Pathways to Precision Medicine in Hypertrophic Cardiomyopathy: Opportunities and Challenges in Plasma Proteomics.
作者信息
Tahir Usman A
机构信息
Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
出版信息
Circ Heart Fail. 2025 Jan;18(1):e012593. doi: 10.1161/CIRCHEARTFAILURE.124.012593. Epub 2024 Dec 19.
Abstract
摘要
相似文献
1
Pathways to Precision Medicine in Hypertrophic Cardiomyopathy: Opportunities and Challenges in Plasma Proteomics.肥厚型心肌病精准医学之路：血浆蛋白质组学的机遇与挑战
Circ Heart Fail. 2025 Jan;18(1):e012593. doi: 10.1161/CIRCHEARTFAILURE.124.012593. Epub 2024 Dec 19.
2
Prediction of Major Adverse Cardiovascular Events in Patients With Hypertrophic Cardiomyopathy Using Proteomics Profiling.采用蛋白质组学分析预测肥厚型心肌病患者的主要不良心血管事件。
Circ Genom Precis Med. 2022 Dec;15(6):e003546. doi: 10.1161/CIRCGEN.121.003546. Epub 2022 Oct 11.
3
Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy.蛋白质组学分析揭示了肥厚型心肌病的一种独特的高风险分子亚型。
Heart. 2022 Oct 28;108(22):1807-1814. doi: 10.1136/heartjnl-2021-320729.
4
Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy.家族性肥厚型心肌病中心脏性猝死与终末期心力衰竭的共存
J Am Coll Cardiol. 1993 Aug;22(2):489-97. doi: 10.1016/0735-1097(93)90054-5.
5
Hypertrophic Cardiomyopathy as a Cause of Sudden Cardiac Death in the Young: A Meta-Analysis.肥厚型心肌病作为年轻人心脏性猝死的原因：一项荟萃分析。
Am J Med. 2016 May;129(5):486-496.e2. doi: 10.1016/j.amjmed.2015.12.027. Epub 2016 Jan 20.
6
Prophylactic implantable defibrillators for hypertrophic cardiomyopathy: disarray in the era of precision medicine.肥厚型心肌病的预防性植入式除颤器：精准医学时代的混乱局面
Circ Arrhythm Electrophysiol. 2015 Aug;8(4):763-6. doi: 10.1161/CIRCEP.115.003140.
7
Novel Multiplexed Plasma Biomarker Panel Has Diagnostic and Prognostic Potential in Children With Hypertrophic Cardiomyopathy.新型多重血浆生物标志物panel 在儿童肥厚型心肌病中有诊断和预后潜力。
Circ Genom Precis Med. 2024 Jun;17(3):e004448. doi: 10.1161/CIRCGEN.123.004448. Epub 2024 Jun 7.
8
Evolving Epidemiology of Hypertrophic Cardiomyopathy: Shifting the Focus From Instant to Lifetime Risk Awareness.肥厚型心肌病不断演变的流行病学：将关注点从即刻风险转移到终身风险意识
Circ Heart Fail. 2022 Sep;15(9):e009873. doi: 10.1161/CIRCHEARTFAILURE.122.009873. Epub 2022 Sep 7.
9
Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy.种族与肥厚型心肌病患者疾病表现和临床结局的相关性。
JAMA Cardiol. 2020 Jan 1;5(1):83-91. doi: 10.1001/jamacardio.2019.4638.
10
Impact of type 2 diabetes mellitus on mid-term mortality for hypertrophic cardiomyopathy patients who underwent septal myectomy.2 型糖尿病对接受室间隔心肌切除术的肥厚型心肌病患者中期死亡率的影响。
Cardiovasc Diabetol. 2020 May 13;19(1):64. doi: 10.1186/s12933-020-01036-1.
本文引用的文献
1
Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy From Other Cardiomyopathies With Left Ventricular Hypertrophy.综合蛋白质组学分析鉴定循环生物标志物以区分肥厚型心肌病与其他伴有左心室肥厚的心肌病。
Circ Heart Fail. 2025 Jan;18(1):e012434. doi: 10.1161/CIRCHEARTFAILURE.124.012434. Epub 2024 Nov 11.
2
Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.肌节性肥厚型心肌病不良临床特征和事件的蛋白质生物标志物
Circ Heart Fail. 2024 Dec;17(12):e011707. doi: 10.1161/CIRCHEARTFAILURE.124.011707. Epub 2024 Nov 5.
3
Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.全面蛋白质组学分析人类心肌组织，揭示肥厚型心肌病中失调的信号通路。
J Am Coll Cardiol. 2024 Nov 12;84(20):1999-2011. doi: 10.1016/j.jacc.2024.07.043. Epub 2024 Oct 2.
4
Proteomic signatures improve risk prediction for common and rare diseases.蛋白质组学特征可提高常见和罕见疾病的风险预测。
Nat Med. 2024 Sep;30(9):2489-2498. doi: 10.1038/s41591-024-03142-z. Epub 2024 Jul 22.
5
MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy.MDM2 调控 HIF 信号导致肥厚型心肌病中小血管功能障碍。
Circulation. 2023 Dec 5;148(23):1870-1886. doi: 10.1161/CIRCULATIONAHA.123.064332. Epub 2023 Oct 27.
6
Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods.蛋白质组学分析平台对比：利用遗传学和临床特征比较适体和抗体方法。
Sci Adv. 2022 Aug 19;8(33):eabm5164. doi: 10.1126/sciadv.abm5164.
7
Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy.综合蛋白质组学分析揭示肥厚型心肌病的循环生物标志物。
Circ Heart Fail. 2021 Jul;14(7):e007849. doi: 10.1161/CIRCHEARTFAILURE.120.007849. Epub 2021 Jul 1.
8
Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.常见的遗传变异和可调节的风险因素是肥厚型心肌病易感性和表现性的基础。
Nat Genet. 2021 Feb;53(2):135-142. doi: 10.1038/s41588-020-00764-0. Epub 2021 Jan 25.
9
Omics and Cardiometabolic Disease Risk Prediction.组学与心血管疾病风险预测。
Annu Rev Med. 2020 Jan 27;71:163-175. doi: 10.1146/annurev-med-042418-010924.
10
Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.肥厚型心肌病 NHLBI 登记处的不同亚组。
J Am Coll Cardiol. 2019 Nov 12;74(19):2333-2345. doi: 10.1016/j.jacc.2019.08.1057.
Zotero 插件